20-F: Abivax Reports Strong Phase 3 UC Data, Secures Major Funding

Abivax announced positive Phase 3 induction trial results for obefazimod in ulcerative colitis and significantly bolstered its financial position with a $747.5 million public offering, extending its cash runway into Q4 2027.

Summary

• Abivax reported a net loss of €336.1 million for the year ended December 31, 2025, an increase from €176.2 million in 2024 and €147.7 million in 2023.
• Accumulated tax losses reached €912.9 million as of December 31, 2025.
• Research and development expenses increased by 21% to €177.8 million in 2025, primarily due to progression of UC and CD clinical trials and increased CMC/supply chain costs.
• General and administrative expenses rose by 105% to €67.7 million in 2025, largely driven by increased employer taxes and social contributions related to Free Shares (AGAs) due to a significant rise in share price.
• The company completed a public offering in July 2025, raising approximately $747.5 million (€637.5 million) in gross proceeds.
• Cash and cash equivalents, along with other short-term investments, stood at €530.4 million as of December 31, 2025, providing a forecasted cash runway into the fourth quarter of 2027.
• Positive top-line data from two Phase 3 ABTECT induction trials for obefazimod in moderately to severely active ulcerative colitis were announced in July 2025, showing significant clinical remission rates (20.8% for 50mg, 17.6% for 25mg vs. 4.4% placebo).
• Obefazimod demonstrated a highly differentiated placebo-adjusted clinical response rate across all lines of bio-naive and bio-refractory patients, including JAK inhibitor-resistant patients, with no major safety concerns.
• A Phase 2b clinical trial for obefazimod in Crohn's disease was initiated in Q4 2024, with top-line induction data expected in Q4 2026.
• Preclinical data supports obefazimod's anti-fibrotic potential in IBD, showing significant reduction in PRO-C3 and inhibition of fibroblast activation in models.
• The company established an At-the-Market (ATM) program in November 2024 to issue up to $150.0 million in ADSs, which has not yet been utilized.
• All debt related to Kreos/Claret and Heights Financings was repaid or converted into ordinary shares by December 2025, releasing the company from associated commitments.
• Material weaknesses in internal controls over financial reporting persist as of December 31, 2025, related to risk assessment, control activities, information/communication, and monitoring activities, primarily due to insufficient internal control knowledge and governance.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing as highly positive due to the strong Phase 3 induction trial results for obefazimod in UC, which significantly de-risks the lead asset, coupled with a substantial capital raise that provides a solid financial runway for continued development and potential commercialization.

Positives

• Obefazimod's Phase 3 ABTECT induction trials in ulcerative colitis showed statistically significant and clinically meaningful results, with 20.8% clinical remission for 50mg and 17.6% for 25mg versus 4.4% for placebo.
• The drug candidate demonstrated a favorable tolerability profile with overall rates of serious adverse events and discontinuations similar to placebo, indicating potential clinical differentiation from existing therapies.
• Obefazimod showed efficacy in a highly refractory patient population, including those who previously failed JAK inhibitors, with a >25% difference from placebo in clinical response across treatment lines for the 50mg dose.
• A significant public offering in July 2025 raised approximately $747.5 million in gross proceeds, substantially strengthening the company's liquidity.
• The company's cash and short-term investments of €530.4 million as of December 31, 2025, are expected to fund operations into Q4 2027, providing a 12-month cash runway post-NDA submission for UC.
• Preclinical data suggests obefazimod has anti-fibrotic effects, which could be a significant advantage in Crohn's disease where fibrosis is a major complication.
• All debt related to the Kreos/Claret and Heights Financings was either converted into equity or fully prepaid by December 2025, reducing financial liabilities and associated collateral pledges.
• The company was admitted to the CAC Mid 60 and SBF 120 indices in September 2025, enhancing its visibility in European markets.

Negatives

• The company reported a substantial net loss of €336.1 million for the year ended December 31, 2025, an increase of 91% from the prior year, indicating continued heavy investment without product revenue.
• Accumulated tax losses have grown to €912.9 million as of December 31, 2025, highlighting a long history of unprofitability.
• General and administrative expenses increased significantly by 105% in 2025, largely due to higher employer taxes and social contributions on equity awards, which are sensitive to share price fluctuations.
• The company has material weaknesses in its internal controls over financial reporting, specifically in risk assessment, control activities, information/communication, and monitoring activities, due to insufficient internal control knowledge and governance.
• The Russia-Ukraine war continues to pose risks to the company's business, including access to raw materials, logistics, clinical trial performance (with sites in Ukraine), and future financing, though Russia and Belarus are excluded from Phase 3 programs.

Risks

• The company is a clinical-stage biopharmaceutical company with a limited operating history and no approved products or historical product revenues, making future prospects and financial results difficult to assess.
• Considerable losses are anticipated to continue and may increase in the future, with no assurance of achieving or sustaining profitability.
• Drug candidates must undergo costly, rigorous, and highly regulated preclinical studies and clinical trials, whose time of completion, number, and outcomes are uncertain.
• Heavy dependence on the success of obefazimod; regulatory approval is not guaranteed, and without it, drug candidates cannot be marketed.
• Clinical failure can occur at any stage of development, and earlier trial results are not necessarily predictive of future outcomes.
• Difficulty enrolling patients in clinical trials could delay or adversely affect clinical development activities.
• Safety or supply issues with combination use products could delay or prevent development and approval of therapeutic candidates.
• Data from clinical trials conducted outside the U.S. may not be accepted by the FDA, potentially delaying development plans.
• Interim, top-line, and preliminary data from clinical trials and preclinical studies may change as more patient data become available and are subject to audit and verification.
• Disruptions at the FDA and other government agencies due to funding shortages or global health concerns could hinder product development, review, approval, or commercialization.
• The FDA and other regulatory agencies actively enforce laws and regulations prohibiting the promotion of off-label uses, which could lead to significant liability.
• Inability to find industrial partners for clinical and commercial development of obefazimod could negatively impact growth and outlook.
• Inability to conduct or contract others to conduct animal testing in the future could harm research and development activities.
• Difficulties in managing organizational expansion could disrupt operations.
• International operations expose the company to various risks, including foreign currency exchange rate fluctuations, differing reimbursement regimes, and compliance with diverse laws.
• Market opportunities for drug candidates may be limited to specific patient populations or be smaller than estimated.
• Reluctance of physicians, healthcare payors, patients, or the medical community to adopt new drugs, and the availability of competing drugs, could adversely impact sales.
• Global economic conditions, including geopolitical developments, could materially adversely impact demand for drug candidates and access to financing.
• Changes to trade policy, tariffs, and import/export regulations may have a material adverse effect on business.
• Reliance on a small number of third-party suppliers and manufacturers, in some cases single-source, poses supply chain risks.
• Dependence on third parties to conduct preclinical studies and clinical trials; their failure to meet contractual duties or deadlines could harm the business.
• Inability to retain key executives and attract, retain, and motivate qualified personnel could impede objectives.
• Risk of misconduct or other improper activities by employees, principal investigators, consultants, and commercial partners, including noncompliance with regulatory standards and insider trading.
• Limited infrastructure in market access, sales, marketing, and distribution, requiring significant investment and competition for talent.
• Numerous competitors in the market for therapeutic treatments of inflammatory diseases, with many having greater resources and experience.
• Dependence on collaboration and strategic alliances with third parties, which may not be successful or may be terminated.
• Partnerships and licensing agreements relating to technologies may not be successful, threatening the use and operation of technology platforms.
• Reimbursement of drugs and treatments is beyond the company's control and is uncertain, impacting market acceptance and profitability.
• Inability to protect intellectual property rights or if these rights are insufficient could decrease the ability to exclusively commercialize drug candidates.
• Risk of being sued for infringing or misappropriating the intellectual property rights of third parties, leading to costly litigation and development delays.
• Patent terms may be inadequate to protect competitive position for an adequate amount of time.
• Inability to protect the confidentiality of trade secrets and know-how could harm business and competitive position.
• Intellectual property rights may not address all potential threats to competitive advantage.
• The business is subject to a restrictive and changing regulatory framework, potentially increasing requirements and costs for marketing authorizations.
• Subject to healthcare laws and regulations which may require substantial compliance efforts and could expose the company to criminal sanctions, civil and administrative penalties.
• Current and future health reform measures could adversely affect business operations, including potential drug price reductions and increased enforcement on advertising.
• The market price of equity securities may be volatile, and purchasers of ADSs could incur substantial losses.
• If securities or industry analysts do not publish research or publish inaccurate or unfavorable research, the price of ADSs and trading volume could decline.
• Requirements of being a U.S. public company may strain resources and divert management's attention.
• Increased risk of securities class action litigation.
• No current intention to pay dividends, and French law may limit dividend distribution.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future, not anticipating profitability until regulatory approval and successful commercialization of obefazimod or future drug candidates. The cash and short-term investments are expected to fund operations into Q4 2027, providing a 12-month cash runway following the planned NDA submission for obefazimod in UC, assuming positive Phase 3 maintenance trial results. The company plans to announce top-line data from the Phase 3 ABTECT maintenance trial in late Q2 2026 and expects to submit its NDA with the FDA in Q4 2026. Top-line induction data from the Phase 2b Crohn's disease trial is anticipated in Q4 2026. The company also aims to select an obefazimod follow-on candidate in 2026 and explore combination therapy opportunities in IBD.

Management Comments

• Marc de Garidel, Chief Executive Officer, has more than 40 years of experience in the pharmaceutical and biotechnology sector, including 12 years as CEO of pharmaceutical and biotechnology companies.
• Didier Blondel, Executive Vice President, Chief Financial Officer and Board Secretary, has over 20 years of senior finance positions at Sanofi and Sanofi Pasteur MSD.
• Fabio Cataldi, Chief Medical Officer, has over 20 years of experience in the development and commercialization of innovative therapies, with expertise in immunology and gastroenterology.
• Sylvie Grégoire, Chair of the Board, is a distinguished pharmaceutical and biotech executive with over 30 years in international leadership roles.
• Dominik Höchli, Independent Director, brings over two decades of leadership experience in global biopharma, including a 20-year tenure at AbbVie/Abbott.

Industry Context

StockSavvy.ai notes that Abivax operates in a highly competitive biotechnology and pharmaceutical industry, particularly in chronic inflammatory diseases like IBD. The market is characterized by significant and rapid technological change, with numerous large pharmaceutical and biotech companies developing new treatments. Obefazimod's novel mechanism of action (enhancing miR-124 expression) and oral administration could offer a differentiated profile compared to existing injectable biologics and JAK inhibitors, which often have safety concerns and waning efficacy. The industry is seeing a trend towards oral small molecules and combination therapies to address unmet needs, positioning Abivax's strategy well. Recent acquisitions of TL1A molecules by major players like Merck, Roche, and Teva/Sanofi indicate a strong competitive landscape for newer targets in IBD.

Comparison to Industry Standards

• Obefazimod's Phase 3 induction clinical remission rates (20.8% for 50mg, 17.6% for 25mg vs. 4.4% placebo) compare favorably to some existing advanced therapies, such as ozanimod (Zeposia), which achieved 18% clinical remission vs. 6% placebo in its UC Study 1 induction period. For TNF inhibitor-experienced patients, ozanimod showed only 10% clinical remission vs. 5% placebo, suggesting obefazimod's potential differentiation in refractory populations.
• The observed tolerability profile of obefazimod, with similar rates of serious adverse events and discontinuations to placebo, contrasts with JAK inhibitors (e.g., Pfizer's Xeljanz, AbbVie's Rinvoq) which carry black box warnings for serious cardiac events, cancer, blood clots, and death, as highlighted by FDA and EMA warnings in 2021 and 2023.
• The company's strategy to develop an oral small molecule aligns with patient and physician preference for convenience over injectable biologics (e.g., AbbVie's Humira, Johnson & Johnson's Stelara, Eli Lilly's Mirikizumab), potentially leading to higher medication adherence.
• Preclinical data showing obefazimod's anti-fibrotic effects in IBD models (50% reduction in PRO-C3, strong inhibition of fibroblast activation) could position it uniquely against competitors, as no efficacious anti-fibrotic treatment for IBD patients is currently available.
• The pursuit of combination therapies with obefazimod, leveraging its novel MOA, is consistent with emerging industry trends, as seen with J&J's fixed-dose combination phase 2 trial of guselkumab plus golimumab, aiming for higher efficacy rates than monotherapy.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any legal proceedings that are likely to have a material adverse effect on its business.

Related Party Transactions

• Employment agreements and other compensation arrangements, including equity compensation, with directors and executive officers are in the ordinary course of business.
• An intellectual property assignment agreement was entered into with former CEO Hartmut Ehrlich on July 7, 2021, to transfer IP rights on certain patents to the Group, with no compensation paid for the transfer.
• A transition protocol was entered into with Dr. Hartmut Ehrlich in April 2023 upon his retirement as CEO, including a total compensation of €100 thousand as an advisor and a departure indemnity of €1,210 thousand.
• A management contract was entered into with CEO Marc de Garidel on April 18, 2023, and AGA plans were granted to him in 2023, 2024, and 2025.
• A management contract was entered into with Chairman of the Board Sylvie Grégoire in July 2024, and BSA plans were granted to her in 2024 and 2025.
• The company has a related-party transaction policy requiring Board review and approval/ratification for transactions with general managers, directors, 10%+ shareholders, and their affiliates, excluding ordinary course transactions at arm's length.

Stakeholder Impact

• Shareholders: Significant dilution from past and future equity issuances, but also potential for value appreciation from positive clinical trial results and successful commercialization. Increased transparency and governance due to dual listing. Potential for reduced voting power for ADS holders due to French law on double voting rights.
• Employees and Management: Benefit from equity incentive plans (BCEs, BSAs, AGAs) designed to attract, retain, and motivate, aligning their interests with shareholder value. Management changes indicate strategic adjustments to leadership.
• Patients: Potential for a new, differentiated oral treatment option (obefazimod) for chronic inflammatory diseases like UC and CD, addressing unmet needs with a favorable safety profile.
• Regulatory Authorities: Ongoing scrutiny and compliance requirements for drug development, manufacturing, and marketing. The company's internal control weaknesses could attract regulatory attention.
• Third-Party Payors: Future market acceptance and sales of approved drugs will depend heavily on coverage and adequate reimbursement, which is subject to complex and evolving national and international policies.
• Suppliers and Manufacturers: Continued reliance on a small number of third-party suppliers and CMOs, creating dependence and potential risks to supply continuity and quality.

Next Steps

• Report top-line data from the Phase 3 ABTECT maintenance trial in late second quarter of 2026.
• Submit New Drug Application (NDA) with the FDA in the fourth quarter of 2026, assuming positive Phase 3 maintenance trial results.
• Announce Phase 2b induction trial top-line results for obefazimod in Crohn's disease in the fourth quarter of 2026.
• Proceed to a Phase 3 clinical trial for obefazimod in Crohn's disease, if Phase 2b results are positive.
• Announce an obefazimod follow-on candidate selection in 2026.
• Assess external early drug candidates in chronic inflammatory diseases to strengthen the R&D portfolio.
• Continue to evaluate oral and injectable combination therapy candidates with obefazimod in UC, with additional preclinical data expected in 2026.
• Further optimize and scale up the supply chain for obefazimod to ensure capacity for expected commercial supply.
• Establish a second source manufacturer for obefazimod to ensure continuity of product supply.
• Remediate identified material weaknesses in internal controls over financial reporting.

Key Dates

Recommendation

The positive Phase 3 induction trial results for obefazimod in ulcerative colitis are a significant de-risking event for the company's lead asset, demonstrating strong efficacy and a favorable safety profile. This clinical success, combined with a substantial capital raise of $747.5 million in July 2025, provides a solid financial foundation and extends the cash runway into Q4 2027, mitigating immediate liquidity concerns. While the company continues to incur losses and faces inherent biotech development risks, the strong clinical data and robust financing position it well for upcoming milestones, including Phase 3 maintenance data and NDA submission. The potential for obefazimod to be a first-line advanced oral therapy in a large market, coupled with promising preclinical data in Crohn's disease and anti-fibrotic effects, suggests significant long-term growth potential for investors with a higher risk tolerance.

Keywords

Obefazimod, Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Disease, miR-124, Clinical Trials, Phase 3, Biotechnology, Pharmaceuticals, SEC Filing, Financial Results, Capital Raise, Drug Development, Immunology, Anti-fibrotic